OnKure Therapeutics Business Summary

OnKure Therapeutics, Inc. (OKUR) is a clinical-stage biopharmaceutical company that operates as a pure-play precision oncology developer, currently generating no revenue as its assets remain in clinical trials. The company’s business model is centered on the discovery and development of small-molecule inhibitors that target biologically validated drivers of cancer, with a primary focus on its lead candidate, OKI-219, a highly selective PI3KαH1047R inhibitor. OnKure operates through a single business segment dedicated to clinical research and drug discovery, leveraging a structure-based drug design platform to create therapies with superior selectivity profiles intended to reduce the off-target toxicities common in first-generation treatments. In the competitive landscape, OnKure contends with Prelude Therapeutics, Vor Biopharma, and industry giant Novartis, which markets the PI3K inhibitor Piqray. OnKure distinguishes itself by focusing on mutant-specific selectivity to preserve wild-type PI3Kα function, positioning itself as a high-potential, niche innovator in the multibillion-dollar breast cancer and solid tumor markets. The company is led by President and CEO Dr. Nicholas A. Saccomano, a seasoned biopharmaceutical executive who previously served as Chief Science Officer at Pfizer’s Boulder facility and held senior roles at Array BioPharma. The current executive suite includes Chief Financial Officer Jason Leverone, Chief Medical Officer Dr. Samuel Agresta, and Chief Scientific Officer Dr. Dylan Hartley, all of whom bring extensive experience from oncology-focused firms like Reneo Pharmaceuticals and Infinity Pharmaceuticals. OnKure was originally co-founded by Dr. Tony Piscopio, a veteran medicinal chemist and former CEO. Following its 2024 merger with Reneo Pharmaceuticals, the company is backed by a high-pedigree roster of institutional investors, including Perceptive Advisors, Cormorant Asset Management, Samsara BioCapital, and Acorn Bioventures. The Board of Directors is chaired by Dr. Andrew Phillips and includes notable industry figures such as Michael Grey and Edward T. Mathers, providing deep strategic oversight as the company advances toward critical Phase 1/2 clinical readouts in 2026.